Late doxorubicin cardiotoxicity

Anticancer Drugs. 1992 Aug;3(4):367-9. doi: 10.1097/00001813-199208000-00008.

Abstract

The occurrence of late congestive heart failure (CHF) as the first clinical manifestation of doxorubicin-induced cardiac toxicity is unusual in children and very rare in adults. However, subclinical cardiac dysfunction is commonly detected in children years after treatment with doxorubicin containing regimens. We report a 58 year old woman who developed stage IV CHF 7 years after completion of doxorubicin treatment for carcinoma of the ovary. Occult cardiac dysfunction was first demonstrated by radionuclide angiography 6 years prior to the occurrence of the clinical manifestations. This unique course of the disease and the management of the CHF are discussed.

Publication types

  • Case Reports

MeSH terms

  • Coronary Angiography
  • Dobutamine / therapeutic use
  • Doxorubicin / adverse effects*
  • Female
  • Heart Failure / chemically induced*
  • Humans
  • Middle Aged
  • Time Factors
  • Ventricular Function, Left / drug effects

Substances

  • Dobutamine
  • Doxorubicin